Post-Activity Test and Activity Evaluation POST TEST Question Title * 1. High-risk patient populations for C. difficile infection include all of the following except: Immunosuppressed Had a prior CDI episode Those with irritable bowel syndrome Recent antimicrobial therapy Question Title * 2. Risk factors for CDI recurrence include all of the following except: Older age Recent hospitalization History of severe CDI episode Termination of gastric acid suppression Question Title * 3. For a patient with multiply recurrent episodes of CDI, the IDSA/SHEA guidelines recommend any of the following treatments except: Vancomycin plus metronidazole Vancomycin plus rifaximin chaser Fidaxomicin Fecal microbiota transplantation Question Title * 4. A 64-year-old woman was hospitalized for community-acquired pneumonia and developed an initial episode of C. difficile infection. She was successfully treated with a 10-day course of vancomycin 125 mg given 4 times daily. She returns to the hospital 3 weeks after discharge after experiencing severe abdominal pain and 8 episodes of diarrhea in the past 24 hours. Laboratory testing supports a CDI diagnosis. According to the latest IDSA/SHEA guidelines, appropriate treatment can include any of the following except: Metronidazole plus rifaximin chaser Prolonged tapered vancomycin regimen Pulsed vancomycin regimen Standard dose fidaxomicin Question Title * 5. Clinical trials demonstrate that, compared to vancomycin, the use of fidaxomicin in the treatment of CDI resulted in significantly: Higher overall clinical cure rates Higher clinical cure rates for moderate-to-severe CDI only Lower clinical cure rates in patients with mild infection Lower rates of recurrent infection Question Title * 6. In addition to standard of care antimicrobial therapy, which of the following would most likely reduce the risk of readmission in a patient with CDI and at high risk of recurrence? Concomitant use of IV metronidazole Regular use of probiotics One infusion of bezlotoxumab Concomitant non-C. difficile antimicrobial therapy Next